Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy

Our <i>in vitro</i> studies suggest the potential use of mRNA CD117 CAR T cells as a non-genotoxic preconditioning strategy for patients with high-risk or refractory AML.